Skip to main content
TIANYU BIO-TECHNOLOGY CO.,LTD. logo

TIANYU BIO-TECHNOLOGY CO.,LTD. — Investor Relations & Filings

Ticker · 603717 ISIN · CNE1000030W1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,621 across all filing types
Latest filing 2025-12-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603717

About TIANYU BIO-TECHNOLOGY CO.,LTD.

https://www.tianyubiotech.com/

TIANYU BIO-TECHNOLOGY CO.,LTD. specializes in the research, development, and large-scale production of active pharmaceutical ingredients (APIs) and advanced pharmaceutical intermediates. The company focuses on therapeutic areas such as cardiovascular health, diabetes management, and anti-viral treatments. Its core product portfolio includes various sartan-based intermediates and other complex organic synthesis products. TIANYU BIO-TECHNOLOGY emphasizes rigorous quality management systems and adheres to international regulatory standards to ensure product safety and efficacy. By leveraging advanced chemical synthesis technologies and a robust R&D infrastructure, the company provides customized manufacturing solutions and high-quality chemical components to global pharmaceutical partners. Its operations are characterized by a commitment to technical innovation and process optimization in the synthesis of complex molecules.

Recent filings

Filing Released Lang Actions
向特定对象发行股票证券募集说明书（申报稿）
Capital/Financing Update Classification · 100% confidence The document is a detailed "募集说明书" (Prospectus) for a specific issuance of A shares by Tianyu Bio-Technology Co., Ltd. It includes extensive information about the issuance plan, background, risk factors, financial data, shareholder structure, and regulatory approvals. The text references the China Securities Regulatory Commission (CSRC) and Shanghai Stock Exchange, and discusses the issuance process, pricing, and use of proceeds. This is a formal offering document related to capital raising through a private placement of shares to specific investors. It is not an annual report, earnings release, or management discussion, but a detailed capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the full prospectus, not just an announcement or summary.
2025-12-12 Chinese
关于公司2025年度对外担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Tianyu Bio Technology Co., Ltd. regarding the progress of external guarantees for the fiscal year 2025. It details the guarantee amounts, the parties involved, internal decision procedures, and financial data related to the guarantee. The document is relatively short (3200 characters) and focuses on a specific financial guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial performance analysis. The content is consistent with a regulatory announcement about financing or guarantee activities rather than a full report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company financing activities or capital structure changes such as guarantees.
2025-12-10 Chinese
关于公司2025年度对外担保预计的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianyu Bio Technology Co., Ltd. regarding the progress of external guarantees for the fiscal year 2025. It details the guarantee amounts, the parties involved, internal decision procedures, and financial data of the guaranteed entity. The document is relatively short (3227 characters) and focuses on a specific financial guarantee update rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed management analysis. The content is typical of a regulatory announcement about financing or guarantee activities rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities, specifically guarantees provided by the company.
2025-12-09 Chinese
2025年11月养殖业务主要经营数据公告
Interim / Quarterly Report Classification · 95% confidence The document is a monthly operating data announcement for November 2025 from Tianyu Biological Technology Co., Ltd. It provides key operational metrics such as sales volume, sales revenue, and inventory levels for the pig farming business. The document explicitly states that the data is unaudited and serves as interim data for investor reference. It is not a comprehensive financial report, annual or quarterly, nor is it an earnings release summarizing financial results. The document is short (1343 characters) and focuses on operational data rather than financial statements or management discussion. It is a periodic business update on operational performance, which fits the category of Interim / Quarterly Report (IR) as it contains substantive financial and operational data for a period shorter than a full fiscal year (monthly data). Q4 2025
2025-12-08 Chinese
关于公司2025年度对外担保预计的进展公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's external guarantees for the year 2025, including specifics about guarantee amounts, parties involved, internal decision procedures, and financial data related to the guarantees. It includes information about board and shareholder meeting approvals related to these guarantees. The document is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about the company's guarantee activities and related financing arrangements. It is a typical regulatory filing announcing progress and details about external guarantees, which fits best under the category of Regulatory Filings (RNS). The document length is under 5,000 characters, and it is a formal announcement rather than a full report or presentation.
2025-12-05 Chinese
关于实际控制人部分股份解除冻结的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the unfreezing of shares held by the company's actual controller, including detailed share quantities and percentages. It is a regulatory disclosure about share status changes related to a major shareholder but does not report financial results, management changes, or other report types. It is not a full report but a specific shareholder-related announcement. This fits best under Major Shareholding Notification (MRQ), as it informs about changes in significant share ownership status (unfreezing shares of a major shareholder). The document length is short and focused on shareholding details, confirming MRQ classification.
2025-11-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.